Phenibut Instructions
Buy Phenibut Capsules with Drug Sheet
| International Non-Proprietary Name (INN) | aminophenyl butyric acid (Phenibut) |
| Dosage form | pills (250 mg) |
| Structure | 1 pill contains: Active ingredient: Aminophenyl butyric acid hydrochloride – 250 mg; Excipients: lactose 181.4mg, potato starch 63.6mg, calcium stearate 5.0mg. |
| Description | round, biconvex pills of white or white with a yellowish tint color with a facet and a risk |
| Pharmacological classification | other psychostimulants and nootropic agents |
| ATC code | N06BX22 |
The information presented on the drug instruction pages is a translation of official instructions from the manufacturers and does not reflect the opinions or views of the CosmicNootropic team. This content is provided for informational purposes only and should not be interpreted as company endorsement or opinion.
- Pharmacodynamics
- Pharmacokinetics
- Intended Uses
- Contraindications
- Dosage and Administration
- Side Effects
- Overdose
- Drug Interaction
- Special Precautions
- Pregnancy and Lactation
- Influence on the Ability to Drive Vehicles and Operate Mechanisms
- Storage Conditions
- Shelf Life
- Manufacturer
Pharmacodynamics
Phenibut® normalizes metabolic processes in the nerve cells of the brain. The active substance of the drug Phenibut (aminophenyl butyric acid hydrochloride) can be considered as a derivative of γ-aminobutyric acid (GABA) or as a derivative of β-phenylethylamine. Phenibut has nootropic activity and, as a derivative of GABA, possesses an anxiolytic (tranquilizing) effect. It does not affect cholinergic or adrenergic receptors.
The drug reduces tension, anxiety, fear, and improves sleep, hence it is used for the treatment of neuroses and preoperatively. Phenibut prolongs and enhances the action of hypnotics, narcotics, neuroleptics, and antiparkinsonian agents. Phenibut lacks anticonvulsant activity. It prolongs the latent period of nystagmus and shortens its duration and severity. The drug reduces manifestations of asthenia and vegetative symptoms, including headache, feeling of heaviness in the head, sleep disturbances, irritability, emotional lability, and increases mental performance. Psychological indicators (attention, memory, speed, and accuracy of sensorimotor reactions) improve under the influence of Phenibut, unlike the effects of tranquilizers. Patients with asthenia and emotionally labile patients experience improved subjective well-being from the first days of therapy, increased interest and initiative, and motivation for activity.
Pharmacokinetics
Aminophenyl butyric acid is well absorbed after oral administration and penetrates into all tissues of the body, easily crossing the blood-brain barrier. In the brain tissue, approximately 0.1% of the administered dose of the drug penetrates, with significantly greater penetration observed in individuals of young and elderly age. It is metabolized in the liver, with 80-95% converted into pharmacologically inactive metabolites. About 5% is excreted unchanged by the kidneys, partially excreted in the bile. Cumulation is not observed with repeated administration.
Intended uses – What is phenibut used for?
asthenic and anxiety-neurotic states;
stuttering, tics, and enuresis in children;
insomnia and nighttime anxiety in the elderly;
Meniere’s disease;
dizziness associated with dysfunction of the vestibular analyzer of various origins;
prevention of motion sickness in motion sickness;
as part of complex therapy for alcohol withdrawal syndrome to alleviate psychosomatic and somatovegetative disorders.
Contraindications
Hypersensitivity to the active substance or excipients of the drug, pregnancy, breastfeeding, children under 3 years of age. The drug contains lactose. It should not be used in patients with rare congenital galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.
With caution: Patients with erosive-ulcerative diseases of the gastrointestinal tract should be prescribed lower doses of the drug due to its irritating effect.
Dosage and administration
Orally after meals, with water. Do not chew. Pills can be divided.
Asthenic and anxiety-neurotic states
Adults: 250-500 mg 3 times a day. Maximum single dose – 750 mg (3 tablets), for patients over 60 years old – 500 mg. Administration course – 2-3 weeks. If necessary, the daily dose can be increased to 2500 mg. Administration course – 4-6 weeks. Children: from 3 to 8 years old – 125 mg 2-3 times a day; from 8 to 14 years old – 250 mg 2-3 times a day; children over 14 years old – adult doses.
Stuttering, tics, and enuresis in children
from 3 to 8 years old – 125 mg up to 3 times a day; from 8 to 14 years old – 250 mg 3 times a day; children over 14 years old – adult doses. Insomnia and nighttime anxiety in the elderly: 250-500 mg 3 times a day.
Meniere’s disease, dizziness associated with dysfunction of the vestibular analyzer of various origins
During exacerbation, 750 mg is prescribed 3-4 times a day for 5-7 days, then 250-500 mg 3 times a day for 5-7 days, and then – 250 mg once a day for 5 days. For the treatment of dizziness with vestibular analyzer dysfunctions of vascular and traumatic origin – 250 mg 3 times a day for 12 days.
For the prevention of motion sickness
250-500 mg once 1 hour before the planned journey or at the onset of the first symptoms of motion sickness. The anti-motion sickness effect is enhanced with increasing doses of the drug. The drug is not very effective in severe cases of motion sickness (“intractable” vomiting and others).
As part of complex therapy for alcohol withdrawal syndrome to alleviate psychosomatic and somatovegetative disorders
In the first days of treatment, 250-500 mg 3 times a day and 750 mg at night are prescribed, with a gradual reduction of the daily dose to the usual adult dose.
Side effects
Phenibut, like other medications, may cause side effects, which do not occur in all patients. Usually, Phenibut is well tolerated.
Possible side effects include:
Nervous system disorders: drowsiness and exacerbation of symptoms (at the beginning of treatment), dizziness, headache;
Gastrointestinal disorders: nausea (at the beginning of treatment);
Skin and subcutaneous tissue disorders: allergic reactions (skin rash, itching);
Liver and biliary tract disorders: hepatotoxicity with prolonged use of high doses.
Overdose
The medicinal product is of low toxicity. There have been no reports of overdose.
Symptoms: drowsiness, nausea, vomiting, dizziness. Prolonged use of high doses may lead to eosinophilia, decreased blood pressure, renal impairment, and hepatic steatosis (with intake exceeding 7 g).
Treatment: gastric lavage, symptomatic treatment, maintenance of vital functions. There is no specific antidote.
Drug interaction
For mutual potentiation, aminophenyl butyric acid can be combined with other psychotropic drugs, reducing the doses of aminophenyl butyric acid and the combined medicinal products. Prolongs and enhances the effects of hypnotics, neuroleptics, antiepileptic drugs, and antiparkinsonian drugs.
Special precautions
During prolonged use (more than 2-3 weeks), it is necessary to monitor peripheral blood parameters and liver function every 2-3 weeks.
Pregnancy and lactation
The use during pregnancy and lactation is not recommended due to insufficient clinical observations. In experimental animal studies, no mutagenic, teratogenic, or embryotoxic effects of the drug have been established.
Influence on the Ability to Drive Vehicles and Operate Mechanisms
During treatment, caution should be exercised when driving vehicles and engaging in other potentially hazardous activities requiring increased concentration and psychomotor speed, as some patients may experience disturbances of the central nervous system, such as drowsiness and dizziness.
Storage conditions
Store in a dry dark place at temperatures no higher than 25°C. Keep out of reach of children.
Shelf life
5 years. Do not use the drug after the expiration date indicated on the packaging.
Terms of release from pharmacy
On prescription.
Manufacturer
Usolye Pharm https://usolpharm.ru/
